Search

Displaying results 3741 - 3750 of 5925 in total
  1. Drug

    Ulecaciclib

    go.drugbank.com/drugs/DB21595
    Experimental

    Ulecaciclib has a monoisotopic molecular weight of 496.25 Da.

  2. Drug

    Eciruciclib

    go.drugbank.com/drugs/DB21597
    Experimental

    Eciruciclib has a monoisotopic molecular weight of 488.28 Da.

  3. Drug

    Zevotrelvir

    go.drugbank.com/drugs/DB21638
    Experimental

    Zevotrelvir has a monoisotopic molecular weight of 537.2 Da.

  4. Drug

    Orenasitecan

    go.drugbank.com/drugs/DB21718
    Experimental

    Orenasitecan has a monoisotopic molecular weight of 1470.58 Da.

  5. Drug

    Mocaciclib

    go.drugbank.com/drugs/DB21730
    Experimental

    Mocaciclib has a monoisotopic molecular weight of 609.3 Da.

  6. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with

  7. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    [L17040] Due to a range of its molecular properties - namely its anti-apoptotic effects - tauroursodeoxycholic acid has been examined in inflammatory metabolic diseases and neurodegenerative diseases.

  8. Drug

    Ceftobiprole

    go.drugbank.com/drugs/DB04918
    ApprovedWithdrawn

    Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due

  9. Drug

    Ioversol

    go.drugbank.com/drugs/DB09134
    ApprovedInvestigational

    [L41780] Ioversol is a highly hydrophilic agent considered to be generally safe[L41790]; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol

  10. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors